Daria G. Tolkacheva

Daria G. Tolkacheva

Auto-generated profile, based on publicly available information

Daria G. Tolkacheva

Russian Presidential Academy of National Economy and Public Administration

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TDT. V. Dubinina
T. V. Dubinina
IGI. Z. Gaydukova
I. Z. Gaydukova
VSV. D. Sokolova
V. D. Sokolova
VMV. V. Mladov
V. V. Mladov
DTD. G. Tolkacheva
D. G. Tolkacheva
Эффективность и безопасность генно-инженерных биологических препаратов для лечения анкилозирующего спондилита: систематический обзор и метаанализ препаратов, зарегистрированных в РФ

17 May 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
KSKirill V. Sapozhnikov
Kirill V. Sapozhnikov
ISIrina V. Sorokina
Irina V. Sorokina
Aleksander GusevAleksander Gusev
Aleksander Gusev
NSNatalia A. Sableva
Natalia A. Sableva
VSValeriia D. Sokolova
Valeriia D. Sokolova
ABAnna M. Berezina
Anna M. Berezina
Aim. To assess the effect of febrile neutropenia (FN) prophylaxis with granulocyte colony-stimulating factors (G-CSF) in real-world cancer patients. Materials and methods. We conducted a statistical analysis of anonymized medical records collected in the Webiomed platform. Before analysis, the cards were validated by clinical experts. Electronic records were extracted according to two principles: mentioning D70 in the diagnosis or mentioning a chemotherapy regimen associated with a high risk of FN (20%), requiring the primary prevention of neutropenia. Thus, we obtained two datasets comprising 47.085 (590 patients) and 30.523 (398 patients) records, respectively. Results. Based on the analysis results, the most common risk factors for FN development were highly hematologically toxic chemotherapy regimens and elderly age about 50% in the adult population. In both datasets, the number of female patients prevailed (63.7% in dataset 1, 91.2% in dataset 2), so the most common was breast cancer. Less common were cervical cancer, digestive cancer, and lung cancer. Despite the indications for primary prevention of FN, for safety and importance of achieving the planned dose intensity, it was administered in 18.3% of patients in dataset 1 and 2.3% in dataset 2. No FN or G-CSF-related adverse events were reported in patients who received adequate primary prevention. Conclusion. Some issues related to G-CSF administration in cancer patients were identified. We identified the insufficient provision of patients with primary prevention of FN, which negatively affects survival rates and reduces adherence to antitumor therapy. Real-world data demonstrate the efficacy and safety of FN prevention and planned dose intensity maintance in cytotoxic therapy regimens.

25 December 2022 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TDT. V. Dubinina
T. V. Dubinina
IGI. Z. Gaydukova
I. Z. Gaydukova
NSN. А. Sableva
N. А. Sableva
KSKirill V. Sapozhnikov
Kirill V. Sapozhnikov
VSV. D. Sokolova
V. D. Sokolova
DTD. G. Tolkacheva
D. G. Tolkacheva
Objective – to compare the clinical efficacy and cost-effectiveness of IL-17 inhibitors (SEC, IXE, NTK) in the treatment of adult patients with ankylosing spondylitis (AS) in the healthcare system of the Russian Federation.Material and methods. The study is a sub-analysis of a previously published systematic review and network meta-analysis of the comparative efficacy of biologics in adult patients with AS in the Russian Federation. NNT values were calculated for BASDAI 50 and ASAS 20/40 after 16 weeks of therapy for all studied drugs. CpR was estimated for each biologic after 16 weeks and one year of therapy. Additionally, we carried out an assessment of the financial burden of the most cost-effective strategies for the treatment of AS.Results. The use of NTK is characterized by an average of no more than three patients needed to treat to achieve one ASAS 20/40 or BASDAI 50 response, while on IXE and SEC – no more than 4–5 patients need to be treated, depending on the estimated effectiveness criterion. According to CpR estimate, NTK is the most cost-effective IL-17 inhibitor for the treatment of AS, both after 16 weeks and after one year of therapy.Conclusion. The obtained results make it possible to compare the effectiveness of IL-17 inhibitors from a clinical and economic points of view and can be used both in decision making process of treatment strategies for individual patients, and at the population level – when deciding on the reimbursement of drugs

29 December 2023 in Therapy
Verified
Journal Article
Closed access
MMMazurov V.I. Mazurov
Mazurov V.I. Mazurov
ODOxana M. Drapkina
Oxana M. Drapkina
MMMartynov А.I. Martynov
Martynov А.I. Martynov
SSSayganov S.а. Sayganov
Sayganov S.а. Sayganov
BBBashkinov R.A. Bashkinov
Bashkinov R.A. Bashkinov
MAMoscow Russian Presidential Academy Of National Economy And Public Administration
Moscow Russian Presidential Academy Of National Economy And Public Administration

1 January 2021 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
DTD.G. Tolkacheva
D.G. Tolkacheva
VMV.V. Mladov
V.V. Mladov
VSV.D. Sokolova
V.D. Sokolova

15 April 2022 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
VSV. D. Sokolova
V. D. Sokolova
NSN. A. Sableva
N. A. Sableva
VMV. V. Mladov
V. V. Mladov
DTD. G. Tolkacheva
D. G. Tolkacheva
Background. A systematic literature review helps to identify the main treatment options, and evidence synthesis supports decision-making by comparing clinical efficacy of different treatments. Nowadays new drugs and clinical trials emerge rapidly, so previous network meta-analyses might need to be updated.Objective: to update the existing systematic review and network meta-analysis comparing efficacy of targeted drugs in adult patients with moderate-to-severe plaque psoriasis by adding randomized clinical trials (RCTs) on a new interleukin (IL) 23 inhibitor registered in the Russian Federation – risankizumab, and other RCTs published after 2019; to reassess the Psoriasis Area and Severity Index (PASI) 75/90 numbers of patients needed to treat to achieve clinical response to therapy and the costs per responder for 12–16 weeks and 1 year of therapy.Material and methods. We updated our systematic literature search in the PubMed/MEDLINE and Embase databases. Evidence synthesis included RCTs evaluating the efficacy of adalimumab (ADA), infliximab (INF), etanercept (ETN), certolizumab pegol (CZP), ixekizumab (IXE), netakimab (NTK), secukinumab (SEC), risankizumab (RIS), guselkumab (GUS), ustekinumab (UST), tofacitinib (TOFA), and apremilast (APR) after 12 weeks of therapy. The Bayesian meta-analyses with meta-regression models were performed in order to account for high heterogeneity in patient characteristics and significant differences in the placebo response rates. The considered drugs were ranked based on values of surface under the cumulative ranking curve (SUCRA). Additionally, drug class analyses were carried out.Results. Twenty three new RCTs were added to the network. IL-23 inhibitor RIS, recently approved in the Russian Federation, has joined the group of the most efficacious drugs, such as IL-17 inhibitors NTK and IXE, as well as IL-23 inhibitor GUS. In terms of PASI 75, RIS and IXE showed superiority compared to all tumor necrosis factor alpha (TNFα) inhibitors (INF, ADA, ETN), small molecules (TOFA and APR), and IL-12/23 inhibitor UST, while NTK and GUS were characterized by comparable efficacy with INF and outperformed the remaining drugs. There were no statistically significant differences in efficacy between all the TNFα inhibitors. GUS, IXE, INF, NTK, RIS and SEC demonstrated that no more than 2 patients need to be treated to achieve one PASI 75 response, and no more than 3 need to be treated for one PASI 90 response (according to the upper limit of 95% credible interval). Same as in the previously published study, NTK showed the lowest costs per responder for both 12-week and 1-year periods.Conclusion. The addition of head-to-head trials and increased statistical power of the network revealed previously unidentified significant differences between treatment options for moderate-to-severe plaque psoriasis.